Selank is a synthetic heptapeptide analogue of the immunopeptide tuftsin that laboratories study as a probe of stress-responsive neurochemistry. This review summarizes what preclinical and limited human data actually report about how it intersects GABAergic, peptidase, neuroimmune and neurotrophin signaling — and where the evidence stops.

Selank in brief: origin and the chronic-stress question

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences by extending the C-terminus of tuftsin, an endogenous tetrapeptide immunomodulator, with a Pro-Gly-Pro tripeptide intended to slow enzymatic degradation.¹ That structural lineage matters for interpretation: the molecule was conceived as a "regulatory" peptide expected to nudge existing signaling systems rather than to act as a high-affinity ligand at a single receptor.

Chronic stress is a useful experimental backdrop for such a molecule because it perturbs several systems at once — GABAergic inhibition, monoaminergic turnover, hypothalamic-pituitary-adrenal (HPA) output, and central cytokine tone. Researchers therefore ask whether Selank shifts these stress-perturbed variables back toward their unstressed set-points. The phrase "mood stabilization" in the research literature refers to measured shifts in these biological readouts and in rodent behavioral proxies, not to any clinical mood outcome. Throughout this review, statements describe what studies report in models; none should be read as a description of effects in humans.

GABAergic modulation without a sedative signature

The most examined mechanistic hypothesis is that Selank engages the GABAergic system indirectly. Using radioligand binding on isolated brain-cell plasma membranes, one study reported that Selank altered [3H]GABA binding in a manner consistent with subtype-selective, concentration-dependent positive allosteric modulation of GABA receptors. Notably, the peptide could modulate — and in some conditions block — the activity of diazepam and olanzapine, suggesting overlapping but non-identical binding regions and, importantly, no interaction at the classical benzodiazepine site.¹ This distinction is central to why investigators treat Selank as a modulatory probe rather than a sedative comparator.

Gene-expression work complicates any simple "GABA agonist" reading. In cultured IMR-32 neuroblastoma cells, Selank alone produced no measurable change in the mRNA levels of 84 genes involved in GABAergic neurotransmission; instead, it altered how GABA and olanzapine changed those transcripts when co-applied.³ In other words, the reported activity looks conditional — it appears as a modification of other signals rather than a standalone transcriptional driver. Route of administration adds further nuance: in inbred mice, intraperitoneal dosing increased cortical GABA-receptor marker binding while intranasal dosing instead shifted NMDA-receptor marker binding, and behavioral effects in the elevated plus maze appeared only in the high-anxiety BALB/c strain.⁴ These findings frame Selank as strongly context-dependent, shaped by pharmacokinetics, baseline state and assay design.

Peptidase inhibition and the regulatory-peptide angle

A separate and often underappreciated mechanism concerns enzymatic degradation of endogenous peptides. In human serum, both Selank and its relative Semax inhibited enkephalin-degrading enzymes in a dose-dependent way, with Selank showing a half-maximal inhibitory concentration near 20 micromolar — more potent in that assay than several classical peptidase inhibitors tested alongside it.² Because those enzymes degrade not only enkephalins but a range of regulatory peptides, the authors proposed that part of Selank’s biological activity could stem from transiently extending the lifetime of endogenous signaling molecules rather than from direct receptor occupancy.

This peptidase hypothesis dovetails with the GABAergic observations. If Selank does not consistently change GABAergic gene transcription on its own, yet still shifts downstream signaling, an indirect route — slowing the breakdown of peptides that themselves tune neurotransmission and stress responses — offers a coherent, testable explanation. It remains a hypothesis: the serum data are in vitro, and how meaningfully enzyme inhibition translates to central signaling under chronic stress has not been resolved.

Neuroimmune signaling and the HPA axis under chronic stress

Chronic stress raises circulating and central pro-inflammatory cytokines and elevates glucocorticoid output, and several rodent studies have probed whether Selank interacts with this axis. In a social-confrontation stress model in rats, stress raised serum interleukin-1-beta (IL-1β), interleukin-6 (IL-6) and transforming growth factor-beta-1; administration of Selank was associated with reductions of IL-1β, IL-6 and tumor necrosis factor-alpha and a restoration of IL-4 toward control values.⁶ The authors framed this as "stress-protective" activity at the level of cytokine tone, not as immune suppression.

A restraint-stress study reinforced the HPA connection from a different angle. Rats subjected to chronic restraint developed elevated corticosterone alongside atrophic and inflammatory changes in the colon wall; intraperitoneal Selank was associated with lower corticosterone and reduced pathomorphological signs of stress exposure.⁷ Read together, these reports position any "stabilizing" signal as a secondary, systems-level phenomenon — downstream of stress adaptation rather than a targeted anti-inflammatory action. The magnitude, direction and reproducibility of these cytokine effects vary with the stress paradigm and exposure duration, so they are best treated as pathway-level associations.

BDNF, plasticity and cognition in stressed models

Because chronic stress disrupts synaptic homeostasis in hippocampal and prefrontal circuits, some studies have looked at neurotrophin signaling. In rats given ethanol long-term, Selank was associated with an attenuated ethanol-associated rise in brain-derived neurotrophic factor (BDNF) in the hippocampus and frontal cortex and was associated with preserved object-recognition performance during withdrawal.⁸ The direction here is instructive: the peptide was linked to normalization of a dysregulated BDNF level rather than to an across-the-board increase, consistent with the recurring "restore toward set-point" pattern seen elsewhere.

It is important not to over-read these data. The studies describe modulation of plasticity-related markers under specific stressors; they do not demonstrate synaptic growth, repair, or any functional cognitive benefit that would transfer to humans. Investigators generally treat Selank as a contextual modulator of how synapses respond to prolonged stress, which is why it is classified as a research molecule for mechanistic study rather than a characterized neuroprotective agent.

Human and applied data: what little exists

Human evidence is thin and dated. A comparative clinical study of 62 patients with generalized anxiety disorder and neurasthenia reported that Selank produced anxiolytic effects broadly comparable to the benzodiazepine medazepam, with additional anti-asthenic features, and correlated symptom change with a serum enkephalin marker.¹⁰ This is a small, single older study and does not constitute the kind of replicated, controlled human evidence base expected of an approved medicine.

Applied rodent work outside classic anxiety paradigms has probed related stress-adaptation questions. In an unpredictable chronic mild stress model, the combination of Selank with diazepam returned elevated-plus-maze anxiety indices to pre-stress values more effectively than either compound alone, while Selank alone most reduced anxiety indicators induced by the drug course itself.⁵ In a naloxone-precipitated morphine-withdrawal model, a single anxiolytic-range dose attenuated aversive withdrawal signs, though it remained somewhat less active than diazepam.⁹ These are mechanistically interesting but remain species-specific behavioral proxies. Dose-response relationships were established only within controlled laboratory ranges and do not map onto human constructs, so the findings are best read as pathway-level observations.

Regulatory status, material quality and open gaps

Selank is not approved by the FDA or, to the authors’ knowledge, by other major Western regulators, and it has not completed formal clinical trials in those jurisdictions.¹² Pharmacology reviews explicitly describe it as poorly characterized outside its country of origin and caution that GABA-modulating agents of this class warrant careful evaluation before any broad access.¹¹ For laboratories, an additional practical concern is material identity and purity: forensic analyses of seized preparations have flagged the circulation of research peptides, including Selank and Semax, in poorly defined formulations, underscoring why validated analytical documentation matters for reproducible work.¹² Reconstitution for in-vitro or in-vivo model work typically uses bacteriostatic diluent such as BAC water under the investigator’s own validated protocol.

Substantial mechanistic gaps remain. There is no high-affinity radioligand binding profile that would pin down a primary target; the secondary-messenger consequences of the reported allosteric and peptidase effects are incompletely resolved; and long-term, longitudinal modeling under chronic stress is sparse. The bidirectional crosstalk between monoaminergic transmission and cytokine signaling — central to the "mood stabilization" framing — is still largely inferential. Selank is therefore an open subject of investigation, not a fully mapped model compound.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.